January 6, 2026
Finance

Cyclerion Therapeutics Leads Pre-Market Gainers Following Collaboration Expansion

Significant Movements Seen Among Biotech and Technology Stocks in Early Trading Session

Summary

Cyclerion Therapeutics shares surged by 44.2% in pre-market trading after unveiling an expanded strategic partnership aimed at advancing their closed-loop anesthetic platform. This substantial gain was mirrored by notable pre-market activity across various biotech and technology stocks, reflecting investor responsiveness to recent company developments and announcements.

Key Points

Cyclerion Therapeutics' shares jumped 44.2% in pre-market after expanding its collaboration with Medsteer to advance anesthetic platform CYC-126.
Aeva Technologies rose 24.2% due to its LiDAR tech selection for NVIDIA's DRIVE Hyperion autonomous vehicle platform.
Alumis announced Phase 3 topline data release for psoriasis treatment envudeucitinib, with shares increasing 16.4%.
Several companies showed volatility related to strategic moves including debt settlements, private buyout considerations, and share consolidations.

Cyclerion Therapeutics Inc (NASDAQ:CYCN) experienced a pronounced increase in its stock price during pre-market trading, rising 44.2% to $1.99. This upward movement was triggered by the company's announcement that it is broadening its strategic collaboration with Medsteer Technologies with the objective of advancing the closed-loop anesthetic platform, CYC-126. This news has evidently resonated with investors, sparking heightened interest in the firm's shares prior to the regular market opening.

Alongside Cyclerion, several other companies witnessed significant stock price fluctuations in pre-market sessions, both positive and negative, capturing the attention of market participants. Among the notable gainers was Kandal M Venture Ltd (NASDAQ:FMFC), which climbed 40.9% to $0.47, building on an 8% increase observed on the preceding Monday. This indicates continued investor enthusiasm for the company’s prospects.

Aeva Technologies Inc (NASDAQ:AEVA) posted a strong pre-market performance, with its shares advancing 24.2% to $16.26. This appreciation follows the company’s announcement that its Frequency Modulated Continuous Wave 4D LiDAR technology has been selected for integration into NVIDIA's DRIVE Hyperion autonomous vehicle reference platform. This selection signifies an important validation of Aeva’s technological capabilities within the autonomous vehicle industry.

Similarly, KALA BIO Inc (NASDAQ:KALA) saw its stock increase by 18.3%, reaching $0.73 in pre-market trading. The boost came after the company disclosed the settlement of approximately $10.6 million in debt, a move likely to improve its financial footing and reduce liabilities, attracting buyer interest.

Arbe Robotics Ltd (NASDAQ:ARBE) followed suit with a 17% gain to $1.52, continuing the upward trend from an 8% increase on the previous trading day. Alumis Inc (NASDAQ:ALMS) experienced a 16.4% rise in shares to $9.67 ahead of its scheduled release of topline data from its Phase 3 ONWARD clinical program, which evaluates envudeucitinib in patients with moderate-to-severe plaque psoriasis. The anticipated data release has likely contributed to this proactive market positioning.

OneStream Inc (NASDAQ:OS) saw its shares jump 14.4% to $21.03 following reports that Hg, a private equity firm, is nearing a deal to take the company private. Such news often impacts share prices by altering perceptions of future corporate control and strategy.

Oriental Culture Holding Ltd (NASDAQ:OCG) rebounded 14.1% to $0.043 after a significant drop of 63% on Monday, which resulted from the company’s board approval of a 1-for-220 share consolidation with fractional shares rounded up. This share consolidation likely addressed stock structure concerns that influenced prior price volatility.

Big Tree Cloud Holdings Ltd (NASDAQ:DSY) gained 12.7%, reaching $0.36, following the receipt of two notification letters from Nasdaq, though the content of these notices was not detailed. Zeta Global Holdings Corp (NYSE:ZETA) increased 11.3% to $24.12 after announcing a collaboration with OpenAI to incorporate conversational intelligence and agentic applications into its Athena platform, signaling advancements in its technological offerings.

Conversely, some stocks faced declines in pre-market trading. MOBIX LABS, INC. (NASDAQ:MOBX) fell sharply by 23.8% to $0.25 after announcing a proposed public offering of common stock. Similarly, Fitell Corp (NASDAQ:FTEL) dropped 17.9% to $0.41 following an announced 1-for-8 share consolidation.

Datavault AI Inc (NASDAQ:DVLT) declined 12.4% to $1.26 despite a 43% increase on the prior day. The earlier rise had been driven by plans for a nationwide deployment of its SanQtum technology in partnership with AP Global, aimed at facilitating near-real-time tokenization, data exchange, and monetization applications in 2026.

BitVentures Ltd – ADR (NASDAQ:BVC) slipped 9.7% to $13.33 after a prior 5% increase, and SOLAI Ltd – ADR (NYSE:SLAI) declined 8.5% to $0.77, following a 30% surge on Monday. Parazero Technologies Ltd (NASDAQ:PRZO) decreased 8% to $1.15 after gaining around 6% the previous day.

RedHill Biopharma Ltd (NASDAQ:RDHL) dropped 7.9% to $1.29, despite a 36% rise Monday related to progress in its development program for RHB-102. Zenas Biopharma Inc (NASDAQ:ZBIO) fell 6.6% to $15.50 after a significant 52% drop on Monday, associated with the release of Phase 3 INDIGO trial results of obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD).

Theravance Biopharma Inc (NASDAQ:TBPH) decreased 6% to $17.07 following a 3% drop on Friday, while Starfighters Space Inc (NYSE:FJET) fell 3.3% to $9.08 after a 10% decline on Monday.

The pre-market trading session has demonstrated considerable volatility among biotech, technology, and related sectors with corporate actions such as collaborations, clinical data releases, strategic partnerships, and share restructuring driving volume and price changes. Investors appear attentive to developments impacting company funding, portfolio advancement, and technological innovation as catalysts influencing stock price trajectories prior to the market opening bell.

Risks
  • Despite gains, some stocks like Zenas Biopharma experienced sharp declines due to adverse clinical trial results, indicating clinical risks.
  • Stock consolidations and public offerings observed in firms like Fitell and MOBIX LABS suggest potential dilution and share price pressure risks.
  • Market volatility is evident with large intraday moves, highlighting risks related to market sentiment and reaction to company announcements.
  • Several companies are reliant on successful clinical outcomes or deal closures; failure could negatively affect stock performance.
Disclosure
Education only / not financial advice
Search Articles
Category
Finance

Financial News

Ticker Sentiment
CYCN - positive FMFC - positive AEVA - positive KALA - positive ARBE - positive
Related Articles
Amazon's Investment Propels Beta Technologies Stock in After-Hours Trading

Beta Technologies Inc, an aerospace company specializing in electric aircraft and propulsion systems...

Quince Therapeutics Experiences Massive Stock Surge Amid Strategic Advisor Engagement

Shares of Quince Therapeutics Inc (NASDAQ:QNCX) witnessed a remarkable surge of approximately 300% f...

Charles Schwab Shares Slip Amid Industry Concerns Over AI-Driven Disruption

Shares of Charles Schwab Corp experienced a significant decline following the introduction of an AI-...

Evommune Shares Surge Amid Positive Phase 2a Data for Atopic Dermatitis Treatment

Evommune, Inc. witnessed a sharp increase in its stock price following the release of encouraging to...

Nektar Therapeutics Shares Surge on Strong Atopic Dermatitis Trial Data

Nektar Therapeutics' stock experienced a significant gain following the release of positive 36-week ...

Phio Pharmaceuticals Reports Promising Tumor Clearance in Skin Cancer Trials, Shares Jump

Phio Pharmaceuticals Corp. announced encouraging Phase 1b data for its lead drug candidate PH-762 in...